<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80564">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850147</url>
  </required_header>
  <id_info>
    <org_study_id>SU-2013-041</org_study_id>
    <nct_id>NCT01850147</nct_id>
  </id_info>
  <brief_title>Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen</brief_title>
  <official_title>Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sequential application of low-dose
      short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung
      cancer after failure of conventional therapy. Safety of this regimen will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective of this study is to evaluate the median progression-free survival of this sequential regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the median over-all survival of this regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the disease-control rate of this regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety of this regimen including the rate and grade of adverse effects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib, chemotherapy</intervention_name>
    <description>sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator</description>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of stage IIIB/IV NSCLC

          -  ECOG PS: 0,1

          -  Unidimensional or bi-dimensional measurable disease

          -  Receive prior treatment including first-line platinum-based chemotherapy, standard
             second-line chemotherapy and 1 EGF/EGFR inhibitor

          -  Evidence of disease progression

          -  Life expectancy &gt;12 weeks

          -  Neutrophils &gt; 1.5 109/l, Platelets &gt; 100 109/l, Hemoglobin &gt; 9g/dl, Total bilirubin &lt;
             1.5 UNL, AST (SGOT) and ALT (SGPT) &lt; 2.5 UNL, Alkaline phosphatases &lt; 5 UNL,
             Creatinine &lt; 1 UNL

        Exclusion Criteria:

          -  Pre-existing  hemoptysis of a severity &gt; grade 3 by NCI CTCAE criteria within 4 weeks
             prior to study entry

          -  Uncontrolled hypertension

          -  CHF, angina or arrhythmias

          -  LVEF &lt; 1 UNL

          -  Existing a second malignancy within 5 years

          -  Infected with HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junling Li</last_name>
    <phone>86-13801178891</phone>
    <email>drlijunling@yahoo.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>LI Junling</investigator_full_name>
    <investigator_title>Professor and Chief physician</investigator_title>
  </responsible_party>
  <keyword>sunitinib</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
